Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (June 2024)
15 slides from Sanara Medtech's investor presentation, Jun 20, 2024
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview June 2024 Sanara MedTech Evidence Based Healing
Slide 2: Disclaimers
«© Sanara MedTech Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” ‘our’ or “us’), A
Slide 3: Sales Overview
Sanara MedTech Sales Overview + Products were sold in over 1,080 hospitals/ASCs across 34 states plus the District of Columbia" in the TTM + Products are contracted or approved to be sold in more than 3,000 hospitals/ASCs as of March 31, 2024 + Products are used on average in 500-600 facilities acro
Slide 4: SMTI History: Continuous Innovation and Expansion
SMTI History “s Sanara wire : - es MedTech Continuous Innovation and Expansion 2024 + Tufts peptide license agreement + $55 million debt 2022 facility to drive future growth + Soendia Biologics, LLC acquisition 2020 + InfuSystem 2019 + Sanara uplists to Partnership NASDAQ Capital executed 2018 Marke
Slide 5: Sanara MedTech Product Portfolio
Sanara MedTech Product Portfolio Product Use Cases Focused on Improving Patient Clinical Outcomes BIFORM® Bioactive Moldable Matrix ACTIGEN™ Verified inductive Bone Matrix ALLOCYTE? Plus Advanced Cellular Bone Matrix All three products used for suppart of bone fusion (cervical spine fusian afer trau
Slide 6: Proven, Safe, and Effective
Proven, Safe, and Effective Sanara MedTech CellerateRX® Surgical Overview + CellerateRX® Surgical Powder is a medical hydrolysate of Type | bovine collagen and contains no additives. + Indicated for the management of acute and chronic wounds including: + Surgical wounds + Traumatic wounds + Partial
Slide 7: CellerateRX Surgical Studies
Sanara MedTech CellerateRX® Surgical Studies Supports Wound Management To Reduce Surgical Site Infection Hydrolyzed Collagen Significantly Reduces Surgical Site Infections (Nowrouzi and Awad 2023) Objective: Evaluate the effect of using type 1 hydrolyzed collagen in reducing incidence of surgical si
Slide 8: Tissue Health Plus: Post-Acute Value-Based Care Strategy
value-based component to this strategy. Tissue Health Plus (Formerly WounDerm) Post-Acute Value-Based Care Strategy Exploring ways to accelerate commercialization or find an appropriate partner that can add a 1 value-based wound prevention and treatment program targeting payers and risk bearing enti
Slide 9: Financial Highlights
Financial Highlights Continued Growth, Focus on Profitability Sanara MedTech Overview + Revenue + Inthe first quarter of 2024, the Company generated a record $18.5 million in sales, representing a tenth consecutive record revenue quarter for the Company. + In 2023, the Company generated net revenues
Slide 10: Thank You
Thank You
Slide 11: Appendix
Appendix Sanara MedTech Evidence Based Healing
Slide 12: Non-GAAP Financial Measure
«© Sanara MedTech Non-GAAP Financial Measure Use of Non-GAAP Financial Measure To supplement the Company's financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this press release a
Slide 13: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Reconciliation of Net Loss to Adjusted EBITDA (Unaudited): Three Months Ended March 31, 2024 2023, Net Loss 3 (1,764,184) § (1,177,900) Adjustments Interest expense and other 267,336 6 Depreciation and amortization 1,105,420 718875 ‘Noncash share
Slide 14: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures = Sanara MedTech Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) ‘Three Months Ended ‘Twelve Months Ended December 31, December 31. 2023 2022 2023 2022 Net Loss S (262,444) $ (4,163,485) $ (4,439,902) $ (8,092,328) Adjustments Interest
Slide 15: Reconciliation of GAAP to Non-GAAP Financial Measures
= Sanara MedTech Reconciliation of GAAP to Non-GAAP Financial Measures Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) ‘Three Months Ended September 30, September 30, 2023 2022 Net Loss 3 (1,094,949) S 4,529,252) Adjustments Interest expense and other 188,294 : Income tax benefit : (4,702,